TABLE 1.
Density and Clinical Characteristics
| Minimum Density | ||||
|---|---|---|---|---|
| Overall | 1/2 | 3/4 | p-value | |
| (n = 701) | (n = 487) | (n = 214) | ||
| Age, mean (range) | 58 (28–90) | 61 (29–90) | 52 (30–9) | <.001 |
| Tumor size | 0.699 | |||
| Mean (range) | 1.2 cm (0.1–4.5) | 1.2 cm (0.1–4.5) | 1.2 cm (0.1–4) | |
| Missing | 1 | 1 | 0 | |
| Race | 0.027 | |||
| Asian | 46 (6.6%) | 24 (4.9%) | 22 (10.3%) | |
| Black | 70 (10%) | 55 (11.3%) | 15 (7%) | |
| Other | 12 (1.7%) | 8 (1.6%) | 4 (1.9%) | |
| White | 528 (75.3%) | 367 (75.4%) | 161 (75.2%) | |
| Unknown | 45 (6.4%) | 33 (6.8%) | 12 (5.6%) | |
| Multifocal | 1 | |||
| No | 560 (79.9%) | 388 (79.7%) | 172 (80.4%) | |
| Yes | 139 (19.8%) | 97 (19.9%) | 42 (19.6%) | |
| Missing | (0.3%) | 2 (0.4%) | 0 (0) | |
| Mode of diagnosis | 0.002 | |||
| Mammogram detected | 665 (94.9%) | 475 (97.5%) | 190 (88.8%) | |
| MRI/Ultrasound detected | 27 (3.9%) | 11 (2.3%) | 16 (7.5%) | |
| Missing | 9 (1.3%) | 1 (0.2%) | 8 (3.7%) | |
| MRI | < 0.001 | |||
| No | 598 (85.3%) | 443 (91.0%) | 155 (72.4%) | |
| Yes | 103 (14.7%) | 44 (9.0%) | 59 (27.6%) | |
| pT | 0.592 | |||
| T1/0 | 572 (81.6%) | 395 (81.1%) | 177 (82.7%) | |
| T2 | 125 (17.8%) | 90 (18.5%) | 35 (16.4%) | |
| Missing | 4 (0.6%) | 2 (0.4%) | 2 (0.9%) | |
| Histological subtype | 0.636 | |||
| IDC | 579 (82.6%) | 405 (83.2%) | 174 (81.3%) | |
| ILC | 76 (10.8%) | 53 (10.9%) | 23 (10.7%) | |
| IDC and ILC | 25 (3.6%) | 17 (3.5%) | 8 (3.7%) | |
| Other | 21 (3%) | 12 (2.5%) | 9 (4.2%) | |
| Tumor Type | 0.602 | |||
| Invasive carcinoma only | 134 (19.1%) | 96 (19.7%) | 38 (17.8%) | |
| With DCIS | 566 (80.7%) | 390 (80.1%) | 176 (82.2%) | |
| Missing | 1 (0.1%) | 1 (0.2%) | 0 (0) | |
| Number of sentinel nodes | ||||
| Mean (range) | 3 (0–13) | 2 (0–13) | 3 (1–11) | 0.008 |
| Missing | 20 | 17 | 3 | |
| SLN | 0.103 | |||
| Negative | 580 (82.7%) | 393 (80.7%) | 187 (87.4%) | |
| Positive | 101 (14.4%) | 77 (15.8%) | 24 (11.2%) | |
| Missing | 20 (2.9%) | 17 (3.5%) | 3 (1.4%) | |
| EIC | 0.212 | |||
| NO | 649 (92.6%) | 455 (93.4%) | 194 (90.7%) | |
| Yes | 52 (7.4%) | 32 (6.6%) | 20 (9.3%) | |
| ER | 0.12 | |||
| Negative | 65 (9.3%) | 51 (10.5%) | 14 (6.5%) | |
| Positive | 620 (88.4%) | 428 (87.9%) | 192 (89.7%) | |
| Missing | 16 (2.3%) | 8 (1.6%) | 8 (3.7%) | |
| PR | 0.204 | |||
| Negative | 131 (18.7%) | 98 (20.1%) | 33 (15.4%) | |
| Positive | 552 (78.7%) | 380 (78%) | 172 (80.4%) | |
| Missing | 18 (2.6%) | 9 (1.8%) | 9 (4.2%) | |
| HER2 | 0.761 | |||
| Negative | 622 (88.7%) | 437 (89.7%) | 185 (86.4%) | |
| Positive | 56 (8%) | 38 (7.8%) | 18 (8.4%) | |
| Missing | 23 (3.3%) | 12 (2.5%) | 11 (5.1%) | |
| BMI | ||||
| Median (range) | 27 (15.5–54.1) | 28.6 (17.2–54.1) | 23.6 (15.5–46.9) | < 0.001 |
| Missing | 11 | 5 | ||
pT pathologic tumor stage, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, SLN sentinel lymph node, EIC extensive intraductal component, ER estrogen receptor, PR progesterone receptor